KPI data tables

Arcturus Therapeutics operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.

Arcturus Therapeutics Cash and Cash Equivalents (Quarterly) (usd_millions)
PeriodCash and cash equivalents
Q3 2026184.817
Q2 2026191.483
Q1 2026211.375
Q4 2025230.909
Q3 2025180.36
Q2 2025196.467
Q1 2025216.948
Q4 2024237.028
Q3 2024237.178
Q2 2024260.329
Q1 2024288.396
Q4 2023292.005

Source: Arcturus cash and cash equivalents, balance sheet (thousands, charted as millions). Q3 2026 10-Q (filed 2026-11-05, https://www.sec.gov/Archives/edgar/data/1768224/000119312526449901/arct-20260930.htm): $184,817 at 30 Sep 2026 and $180,360 at 30 Sep 2025. Q2 2026 10-Q (https://www.sec.gov/Archives/edgar/data/1768224/000119312526338090/arct-20260630.htm): $191,483 at 30 Jun 2026 and $196,467 at 30 Jun 2025; restricted-cash reconciliation. Q1 2026 10-Q (https://www.sec.gov/Archives/edgar/data/1768224/000119312526211943/arct-20260331.htm): $211,375 at 31 Mar 2026 and $216,948 at 31 Mar 2025. FY2025 10-K (https://www.sec.gov/Archives/edgar/data/1768224/000119312526088391/arct-20251231.htm): $230,909 at 31 Dec 2025 and $237,028 at 31 Dec 2024. Q3 2025 10-Q (https://www.sec.gov/Archives/edgar/data/1768224/000119312525275758/arct-20250930.htm): $180,360 at 30 Sep 2025 and $237,178 at 30 Sep 2024. Q2 2025 10-Q (https://www.sec.gov/Archives/edgar/data/1768224/000095017025106560/arct-20250630.htm): $260,329 at 30 Jun 2024. Q1 2024 10-Q (https://www.sec.gov/Archives/edgar/data/1768224/000095017024055702/arct-20240331.htm): $288,396 at 31 Mar 2024 and $292,005 at 31 Dec 2023. Runway floor: Q2 2026 Exhibit 99.1 (https://www.sec.gov/Archives/edgar/data/1768224/000119380526001039/e665679_ex99-1.htm). ATM: Q2 2026 10-Q Note 5.

Arcturus Therapeutics R&D Expense by Category (Quarterly) (usd_millions)
PeriodLUNAR-COVIDLUNAR-OTCBARDALUNAR-CF, netEarly-stage programsDiscovery technologiesPayroll and benefitsFacilities and equipment
Q3 20261.1153.07302.04201.7477.3451.676
Q2 20260.3911.870.6422.5930.0921.3418.7311.855
Q1 20260.6022.7180.3246.5310.2431.7547.6191.736
Q4 20252.5850.4912.3832.5020.0581.6710.644.147
Q3 20253.890.781.0433.210.371.729.6932.559
Q2 20253.8312.9012.4594.6290.1672.43910.6112.542
Q1 20255.8091.5762.4817.14802.18713.0432.649

Source: Arcturus Form 10-Q / 10-K segment R&D tables (thousands, charted as millions). Q1 2025 and Q1 2026: Q1 2026 10-Q (https://www.sec.gov/Archives/edgar/data/1768224/000119312526211943/arct-20260331.htm). Q2 2025 and Q2 2026: Q2 2026 10-Q (https://www.sec.gov/Archives/edgar/data/1768224/000119312526338090/arct-20260630.htm). Q3 2026 (three months ended 30 Sep 2026; BARDA and early-stage programs printed as dashes, charted as 0): Q3 2026 10-Q, filed 2026-11-05 (https://www.sec.gov/Archives/edgar/data/1768224/000119312526449901/arct-20260930.htm). Q3 2025: Q3 2025 10-Q (https://www.sec.gov/Archives/edgar/data/1768224/000119312525275758/arct-20250930.htm). Q4 2025: FY2025 10-K (https://www.sec.gov/Archives/edgar/data/1768224/000119312526088391/arct-20251231.htm) annual totals minus Q3 2025 nine-month totals.

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites
Arcturus Therapeutics (ARCT) - KPIs | Sterling